Compass Pathways' Psilocybin Therapy Shows Durable Benefits for Treatment-Resistant Depression in Pivotal Trial

Compass Pathways Plc announced durable benefits for its psilocybin-based therapy, COMP360, in a pivotal trial for treatment-resistant depression. While previous data showed a 39% response rate at six weeks, new results on July 7, 2026, confirm these effects last at least six months. Despite the positive clinical data on durability, the company's shares fell nearly 10%, suggesting investors were underwhelmed by the details.

Psilocybin therapy trial results

• ▪A pivotal study of COMP360 previously showed that 39% of patients had a "clinically meaningful reduction" in depression symptoms after six weeks
• ▪Compass Pathways Plc is developing an experimental psilocybin-based therapy called COMP360 for treatment-resistant depression
• ▪On July 7, 2026, Compass Pathways Plc reported that the reduction in depression symptoms from its COMP360 therapy lasted for at least six months on average
• ▪Shares of Compass Pathways Plc fell almost 10% on July 7, 2026, after the company released its latest trial data